Nebivolol Dosing and Titration
Initial Dosing for Hypertension
For most patients with hypertension, start nebivolol at 5 mg once daily, taken with or without food. 1
- The FDA-approved starting dose is 5 mg once daily for uncomplicated hypertension 1
- This can be used as monotherapy or combined with other antihypertensive agents 1
- Clinical trials demonstrate that 5 mg once daily effectively reduces diastolic blood pressure comparably to standard doses of atenolol, metoprolol, lisinopril, and nifedipine 2
Dose Titration Protocol
If blood pressure control is inadequate after 2 weeks, increase nebivolol by 2.5-5 mg increments every 2 weeks up to a maximum of 40 mg daily. 1
- Titrate at 2-week intervals based on blood pressure response 1
- More frequent dosing adjustments are unlikely to provide additional benefit 1
- Target blood pressure should be <130/80 mmHg per current hypertension guidelines 3
Initial Dosing for Heart Failure
For heart failure with reduced ejection fraction, start nebivolol at 1.25 mg once daily and titrate gradually to a target dose of 10 mg once daily. 3
- The European Society of Cardiology recommends initiating at 1.25 mg once daily 3
- Double the dose every 2-4 weeks if the preceding dose is well tolerated 3
- Target dose is 10 mg once daily, which has been shown to reduce mortality and hospitalizations 3
- Monitor for signs of worsening heart failure, symptomatic hypotension, or excessive bradycardia (pulse <50 bpm) at each visit 3
Dose Adjustments for Renal Impairment
In patients with severe renal impairment (creatinine clearance <30 mL/min), start with 2.5 mg once daily and titrate slowly as needed. 1
- Reduce initial dose by 50% in severe renal dysfunction 1
- Nebivolol has not been studied in dialysis patients 1
- Monitor renal function and blood pressure closely during titration 1
Dose Adjustments for Hepatic Impairment
In patients with moderate hepatic impairment, start with 2.5 mg once daily and titrate slowly as needed. 1
- Reduce initial dose by 50% in moderate hepatic dysfunction 1
- Nebivolol is not recommended in severe hepatic impairment due to lack of safety data 1
Special Considerations for Elderly Patients
No dose adjustment is necessary based on age alone in elderly patients. 1
- Standard dosing of 5 mg once daily can be used in geriatric populations 1
- However, elderly patients may have concurrent renal or hepatic impairment requiring dose reduction 1
Use in Patients with Respiratory Comorbidities
Nebivolol can be safely used in patients with asthma or COPD at standard doses, unlike non-selective beta-blockers. 3, 4
- Asthma is listed as an absolute contraindication for non-selective beta-blockers, but COPD is not a contraindication for cardioselective agents like nebivolol 3
- A controlled study in 24 patients with bronchial hyperreactivity (asthma, COPD) showed that nebivolol 5 mg did not significantly worsen airway obstruction or bronchial hyperreactivity compared to placebo 4
- Another study in 50 patients with coronary disease and COPD demonstrated that nebivolol 5 mg daily had no adverse effect on bronchial patency 5
- Nebivolol's high beta-1 selectivity minimizes beta-2 receptor blockade in the lungs, reducing bronchospasm risk 6
Absolute Contraindications
Do not initiate nebivolol in patients with second or third-degree heart block, sick sinus syndrome without a pacemaker, or sinus bradycardia <50 bpm. 3
- Severe bradycardia and high-grade AV block are absolute contraindications 3
- Unlike other beta-blockers, asthma is not an absolute contraindication for nebivolol due to its high beta-1 selectivity 3, 4
- Decompensated heart failure requires stabilization before initiating beta-blocker therapy 3
Monitoring During Titration
Check blood pressure and heart rate at each visit during dose titration, targeting a resting heart rate of 50-60 bpm unless limiting side effects occur. 3
- Monitor for symptomatic hypotension (dizziness), which often improves with time 3
- Assess for signs of worsening heart failure (increased dyspnea, edema, weight gain) 3
- Consider reducing diuretic or other vasodilator doses if symptomatic hypotension occurs, rather than stopping nebivolol 3
Common Pitfalls to Avoid
Do not discontinue nebivolol abruptly, as this can cause rebound hypertension or worsening angina. 7
- Gradual tapering is essential when discontinuing beta-blocker therapy 7
- In hospitalized patients with worsening heart failure, dose reduction rather than complete discontinuation is preferred 3
- Nebivolol can be cautiously initiated prior to hospital discharge in recently decompensated patients who have improved with other treatments 3